Trials / Recruiting
RecruitingNCT07235527
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (estimated)
- Sponsor
- Saglik Bilimleri Universitesi · Academic / Other
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Conditions
- Age Related Macular Degeneration
- Exudative Age-Related Macular Degeneration
- Anti Vascular Endothelial Growth Factor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept biosimilar (MY-1701P) | Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care. |
Timeline
- Start date
- 2025-11-20
- Primary completion
- 2026-06-20
- Completion
- 2026-08-20
- First posted
- 2025-11-19
- Last updated
- 2025-12-08
Locations
1 site across 1 country: Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07235527. Inclusion in this directory is not an endorsement.